McGuire Investment Group LLC decreased its position in Danaher Corporation (NYSE:DHR – Free Report) by 1.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,839 shares of the conglomerate’s stock after selling 621 shares during the period. McGuire Investment Group LLC’s holdings in Danaher were worth $7,080,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GHP Investment Advisors Inc. raised its stake in Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 99 shares during the last quarter. Sierra Ocean LLC raised its stake in Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock worth $29,000 after acquiring an additional 76 shares during the last quarter. Smallwood Wealth Investment Management LLC purchased a new position in Danaher in the 1st quarter worth $31,000. Dunhill Financial LLC raised its stake in Danaher by 68.4% in the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate’s stock worth $34,000 after acquiring an additional 67 shares during the last quarter. Finally, Costello Asset Management INC purchased a new position in shares of Danaher during the 1st quarter valued at about $41,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.
Danaher Price Performance
NYSE:DHR opened at $212.92 on Thursday. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.41. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $152.46 billion, a PE ratio of 45.30, a price-to-earnings-growth ratio of 2.82 and a beta of 0.77. The stock’s 50-day moving average price is $199.85 and its 200-day moving average price is $197.42.
Danaher Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher’s payout ratio is presently 27.23%.
Insider Transactions at Danaher
In related news, Director Teri List sold 2,778 shares of Danaher stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 11.10% of the company’s stock.
Analyst Ratings Changes
A number of research firms have weighed in on DHR. Barclays reiterated an “overweight” rating and set a $225.00 price objective (up previously from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research note on Friday, June 27th. Scotiabank upgraded Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price objective for the company in a research note on Friday, July 11th. Evercore ISI reduced their price objective on Danaher from $230.00 to $226.00 and set an “outperform” rating for the company in a research note on Tuesday, July 8th. Finally, Royal Bank Of Canada set a $241.00 price objective on Danaher in a research note on Tuesday, September 2nd. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $245.91.
View Our Latest Stock Report on DHR
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Further Reading
- Five stocks we like better than Danaher
- 3 Tickers Leading a Meme Stock Revival
- Datavault AI: The New AI Contender Backed by Big Funding
- 3 Monster Growth Stocks to Buy Now
- CoreWeave: Why the New King of AI Infrastructure Has Room to Run
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Top 3 Dividend Achievers for October: High Yields, Growth Ahead
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.